Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.21.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of segment reporting information
The following table presents information by reportable operating segment for the three months ended March 31, 2021 and 2020 (in thousands):
Consumer Products
Segment
Specialty Pharmaceutical Segment Consolidated Totals
Three months ended March 31, 2021:
Product sales, net $ 4,844  $ —  $ 4,844 
Gross profit $ 2,358  $ —  $ 2,358 
Research and development expense 128  58  186 
Selling, general and administrative expense 5,270  15  5,285 
Operating loss $ (3,040) $ (73) $ (3,113)
Three months ended March 31, 2020:
Product sales, net $ 8,270  $ —  $ 8,270 
Gross profit $ 4,008  $ —  $ 4,008 
Research and development expense 305  1,204  1,509 
Selling, general and administrative expense 7,810  7,819 
Operating loss $ (4,107) $ (1,213) $ (5,320)